# Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19

> **NCT05873374** · PHASE2 · UNKNOWN · sponsor: **Baiya Phytopharm Co., Ltd.** · enrollment: 75 (estimated)

## Conditions studied

- COVID-19 Vaccine
- COVID-19

## Interventions

- **BIOLOGICAL:** 50 μg Baiya SARS-CoV-2 Vax 2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05873374
- **Lead sponsor:** Baiya Phytopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-03
- **Final completion:** 2024-08
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873374, "Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05873374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*